ArticleInternational journal of clinical and experimental pathology2015
Increased circulating interleukin 10-secreting B cells in patients with dilated cardiomyopathy.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis.Frontiers in immunology · 2021Trial
- Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.ESC heart failure · 2025Article
- The Molecular Role of Immune Cells in Dilated Cardiomyopathy.Medicina (Kaunas, Lithuania) · 2023Review
- The Role of B Cells in Cardiomyopathy and Heart Failure.Current cardiology reports · 2022Review
- PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients.International journal of molecular sciences · 2022Article
- The abnormal distribution of peripheral B1 cells and transition B cells in patients with idiopathic dilated cardiomyopathy: a pilot study.BMC cardiovascular disorders · 2022Article
- Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure.Frontiers in pharmacology · 2022Review
- Ex vivo characterization of Breg cells in patients with chronic Chagas disease.Scientific reports · 2021Article
- The role of B cells in heart failure and implications for future immunomodulatory treatment strategies.ESC heart failure · 2020Review
- Decreased levels of regulatory B cells in patients with acute pancreatitis: association with the severity of the disease.Oncotarget · 2018Article
- Role of cytokines and inflammation in heart function during health and disease.Heart failure reviews · 2018Review
- Regulatory B10 cells play a protective role in severe acute pancreatitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRegulatory B cells (Bregs) have recently been implicated in the pathogenesis of autoimmune diseases. However, their role in the pathogenesis of dilated cardiomyopathy (DCM) remains uncertain. We examined the levels of circulating interleukin 10 (IL-10)-secreting Bregs in patients with DCM.
methodsThe frequency of CD19+IL-10+-, CD19+CD5+-, CD19+CD5+CD1d+-, and CD19+CD5+CD1d+IL-10+-B cells in peripheral blood from DCM patients, heart failure (HF) control patients, and healthy controls (HCs) were analyzed by flow cytometry.
resultsDCM and HF control patients showed significantly elevated heart rate, increased left ventricular end-diastolic and left ventricular end-systolic diameters, higher levels of serum brain natriuretic peptide and reduced left ventricular ejection fraction, compared to subjects in the HC group. DCM patients showed significantly elevated levels of circulating CD19+IL-10+-, CD19+CD5+-, CD19+CD5+CD1d+-, and CD19+CD5+CD1d+IL-10+-B cells than HF control and HC patients (all P < 0.05).
conclusionsDCM patients exhibited elevated peripheral blood IL-10-secreting B cell levels, suggesting that IL-10-secreting B cells may play an important role in the pathogenesis of DCM.
Indexed as
Identifiers
26339378PMC4555706W1475998966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.